Big Brand Price Reductions Would Be Needed Without Rebates In Part D, Humana Warns

Insurer suggests manufacturers may not be willing to lower list prices enough to make up financial shortfalls in Medicare Part D that would be caused by restrictions on rebates.

Dollar sign made of pills on blue background

Manufacturers of branded drugs covered by Medicare Part D would need to lower list prices by 28% to 45% to ensure program stability if rebates are no longer allowed, Humana Inc. told HHS in recent comments.

“Removing rebates from the system without negatively impacting the Medicare program and beneficiaries will require drug prices to decrease substantially...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access